Author Archives: admin

Short Read Sequencing Market Share Analysis to 2027 | GenScript., 10x Genomics., Macrogen Inc, QIAGEN, Agilent Technologies, Inc., BGI – Cole of Duty

By adminJuly 21, 2020Gene Therapy Clinics

Global Short Read Sequencing MarketBy Technology (Next- Generation Sequencing, Sanger Sequencing), Product (Instruments, Consumables, Services), Application (Oncology, Clinical Investigation, Reproductive Health, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics), Workflow (Pre- Sequencing, Sequencing, Data Analysis), End- User (Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Market Trends and Forecast to 2027

Global Short Read Sequencing Marketresearch report is very much essential in many ways to grow the business and thrive in the market. The market transformations are highlighted here which occur because of the moves of key players and brands like developments, product launches, joint ventures, merges and accusations that in turn changes the view of the global face ofHealthcareindustry.

Request For Sample Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-short-read-sequencing-market

The major players covered in the short read sequencing market report are Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Illumina, Inc, GENEWIZ, GenScript., 10x Genomics., Macrogen Inc, QIAGEN, Agilent Technologies, Inc., BGI, Fasteris, General Electric, Eurofins Scientific, among other players domestic and global. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Cell and Gene Therapy Digital Conference| Register at:https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Market Analysis and Insights:Global Short Read Sequencing Market

Short read sequencing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 23.15 billion by 2027 growing at a CAGR of 11.34% in the above-mentioned forecast period. Increasing demand for personalized medicines and technological advancement & development in healthcare industry are the factor for the growth of this market.

Increasing adoption of short-read sequencing is the factor for the growth of this market. There is also increasing collaboration & partnership for genetic sequencing which is also expected to drive the market. They are also cost- effective method of detection of genetic abnormalities which also enhance the market growth. Rising demand for advanced technologies for clinical diagnostics is another factor which is also expected to create opportunities for the short read sequencing market in the forecast period of 2020- 2027

This short read sequencing market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Briefour team will help you create a revenue impact solution to achieve your desired goal.

Global Short Read Sequencing Market Scope and Market Size

Short read sequencing market is segmented of the basis of technology, application, product, workflow, and end- users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on technology, short read sequencing market is segmented into next- generation sequencing, and sanger sequencing.

Short read sequencing market is segmented on the basis of product are instruments, consumables, and services.

On the basis of application, the short read sequencing market is segmented on the basis of oncology, clinical investigation, reproductive health, HLA typing/immune system monitoring, metagenomics, epidemiology & drug development, agrigenomics & forensics, and consumer genomics.

The workflow segment is further divided into pre- sequencing, sequencing, and data analysis.

The global short read sequencing market has also been segmented based on the end use into academic research, clinical research, hospitals & clinics, pharma & biotech entities, and other.

For More Details In-Depth Inquiry @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-short-read-sequencing-market

Short Read Sequencing Market Country Level Analysis

Short read sequencing market is analysed and market size insights and trends are provided by country, technology, application, product, workflow, and end- users as referenced above.

The countries covered in the short read sequencing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the digital short read sequencing market due to availability of a regulatory environment supporting the development of genomics while Asia-Pacific is expected to grow at the highest growth rate in the forecast period 2020 to 2027 because of changing reimbursement policy in the country.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Short read sequencing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for short read sequencing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the short read sequencing market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Short Read Sequencing Market Share Analysis

Short read sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to digital short read sequencing market.

Customization Available:Global Short Read Sequencing Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

View Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-short-read-sequencing-market

View post:
Short Read Sequencing Market Share Analysis to 2027 | GenScript., 10x Genomics., Macrogen Inc, QIAGEN, Agilent Technologies, Inc., BGI - Cole of Duty

Homology Medicines Appoints Jeff Poulton to the Board of Directors – GlobeNewswire

By adminJuly 21, 2020Stem Cell Clinic

July 21, 2020 08:00 ET | Source: Homology Medicines, Inc.

- Executive with Extensive Rare Disease Expertise in Global Finance andCommercial Operations -

BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Board of Directors. Mr. Poulton is the Chief Financial Officer at Alnylam. Mr. Poulton brings 25 years of experience to Homologys Board of Directors, including leading finance, business development and commercial operations at companies using differentiated technologies to develop treatments for patients with rare diseases.

I had the pleasure of working with Jeff before, and I know first-hand how his strategic financial and operational leadership contributed to the success of a global rare disease commercial business, said Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. Jeff has also displayed a long-term commitment to help patients and their families, which aligns with Homologys mission to develop our gene therapy and nuclease-free gene editing platform into new treatments and potential cures. He joins at an important time in the development of our pipeline, and we look forward to his guidance as we progress our Phase 1/2 pheNIX gene therapy clinical trial for adults with PKU and work toward bringing our other development candidates to the clinic.

Prior to his role at Alnylam, Mr. Poulton served as CFO at Indigo Agriculture where he supported the initial commercial scale-up of the business, including expansion outside the US. Mr. Poulton previously held various roles of increasing responsibility at Shire Plc, concluding his service as CFO and a member of its Executive Committee and Board of Directors. During his tenure at Shire, Mr. Poulton led the rare disease commercial operations in the US, Latin America, and Asia Pacific, as well as its global rare disease business unit. Prior to Shire, he led corporate finance and business development initiatives in both the energy and materials manufacturing sectors in financial leadership positions at Cinergy Corp and PPG industries. He also served in the US Navy as a Commissioned Officer. Mr. Poulton has an MBA in Finance from the Kelley School of Business at Indiana University and a bachelors degree in Economics from Duke University. He also serves as a member of the Board of Directors at EIP Pharmaceuticals.

I am drawn to companies with transformative technologies, and I believe Homologys genetic medicines platform has the potential to change the lives of patients with rare diseases, said Mr. Poulton. I look forward to working with the team at Homology, many of whom have successful careers in developing and commercializing drugs at prior companies that are continuing to make a positive impact in the lives of patients and families living with rare diseases.

About Homology Medicines, Inc. Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homologys proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicinesin vivoeither through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visitwww.homologymedicines.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our genetic medicines platform; the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; and our position as a leader in the development of genetic medicines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities and potential expansion of our manufacturing facility; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and our other filings with theSECcould cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Original post:
Homology Medicines Appoints Jeff Poulton to the Board of Directors - GlobeNewswire

Higher Steaks Creates World’s First Lab-Grown Bacon and Pork Belly – The Spoon

By adminJuly 21, 2020Adult Stem Cells

United Kingdom based startup Higher Steaks announced today they have successfully created the worlds first lab-grown prototypes for bacon and pork belly.

The production of the first cultivated bacon is big news for those excited for alternatives to industrially produced meat. While 2020 has been a big year for alt-pork, with Impossible launching their plant-based pork at CES and Omnipork debuting their plant-based pork shoulder, this news from Higher Steaks marks the first time bacon and pork belly has been developed from actual animal cells.

The interest in alt-pork shouldnt be surprising since the meat from pigs is the most consumed type of meat in the world. However, countries like China have seen huge viral threats to their pig population, with around half being wiped out in 2019 due to Swine Fever.

According to company CEO Benjamina Bollag, the protoypes took approximately one month to create, developed from a type of a highly adaptable type of stem cell called induced pluripotent stem cells.

In nature, you have adult stem cells and embryonic stem cells, Bollag told The Spoon in an interview. And this is a way of taking any cell in the body and bringing it back to the embryonic state. Which means that you can expand those cells a lot more and you can make any type of tissue.

According to Bollag, the company used stem cells to create muscle tissue, and used a combination of plant protein and fats to round out the prototype. In the future, Bollag says the company intends to use stem cells to create the other parts of the bacon.

For Higher Steaks, creating the worlds first lab-grown bacon prototype is a big accomplishment. Dutch startup Meatable raised $10 million late last year as part of their effort to create a lab-grown pork, while New Age Meats debuted a lab-grown pork sausage prototype in 2018.

If youre excited to try out cultivated bacon, you may have to wait a few years. According to Bollag, lab-grown bacon and pork belly will take a while to get to market.

So I think in the next two to three years, youll start seeing it in the upper end, maybe in select restaurants, small quantities said Bollag. I think for it to be mass market, really price comparison and supermarket, youre looking more around five years.

You can see my full interview with Bollag talking about the development of their bacon and pork belly prototypes below.

The rest is here:
Higher Steaks Creates World's First Lab-Grown Bacon and Pork Belly - The Spoon

Zika: Research team use experimental drug that reduces replication of the virus and prevents microcephaly in mice – Outbreak News Today

By adminJuly 21, 2020Stem Cell Treatment

An international group of researchers have discovered that inhibiting AHR (aryl hydrocarbon receptor), a protein with roles in regulating immunity, stem cell maintenance and cellular differentiation, enables the immune system to combat replication of zika virus in the organism far more effectively. In experiments performed at the University of So Paulos Biomedical Sciences Institute (ICB-USP) in Brazil, the antiviral therapy proved capable of preventing the development of microcephaly and other malformations in mouse fetuses whose mothers were infected while pregnant.

The study wassupported by FAPESP. An article describing the results waspublishedon July 20 in the journalNature Neuroscience.

In the experiments, we used an experimental drug that inhibits AHR and observed a decrease in replication of both zika virus and dengue virus. We now plan to test the effectiveness of the therapy against the novel coronavirus, saidJean Pierre Peron, a professor at ICB-USP and co-principal investigator for the project alongside Cybele Garcia, a virologist at the University of Buenos Aires in Argentina, and Francisco Quintana, a professor of neurology at Harvard Medical School in the United States.

The experimental model used in the study was the same as that used by Perons group in 2016 to prove a causal link between zika virus and microcephaly (read more atagencia.fapesp.br/23286/). On that occasion female mice of the SJL strain, which are much more susceptible to zika infection than other laboratory animals, were infected with the virus between the tenth and twelfth day of pregnancy. When the pups were born, the researchers found a significant reduction in cortical layer thickness, as well as alterations in the number and morphology of cortical and other brain cells. They also found that the virus replicated far more rapidly in placenta and in the pups brains than in other organs.

We repeated this experiment with a difference, Peron said. Shortly before we infected the pregnant females with zika, we began orally administering the AHR inhibitor. The treatment continued until the end of the gestational period. The pups had normal brains in terms of size and weight, and a far lower viral load than the non-treated control group. Viral load was almost undetectable in both the placenta and the central nervous system. In addition, histopathological analysis showed that there was no reduction in cortical layer thickness and that the number of nervous system cells killed by the virus was much smaller.

According to Peron, no adverse effects were observed in the mice treated with the AHR inhibitor, but before the treatment is tested in human volunteers the experiment must be replicated in monkeys.

The study took four years to be completed.Nagela ZanluquiandCarolina Polonio, both PhD candidates at ICB-USP with scholarships from FAPESP, also participated.

Inception

Quintanas laboratory at Harvard is one of the worlds leading centers in studies of the protein AHR. In an interview given toAgncia FAPESP, Quintana said his groupdiscoveredsome years ago that interferons, proteins produced by immune cells in the inflammatory response to infections, control the activation of AHR.

Because interferons are central to the antiviral immune response, we postulated together with Garcias group that AHR might be involved in the suppression of immunity against viruses. We designed anti-AHR therapies and developed nanoparticles and inhibitors for use in the experiments, Quintana said.

Tests performed in the laboratory and in animals confirmed that viruses activate AHR to suppress the hosts immune response. This may occur when a pathogen infects the liver, triggering release of the tryptophan metabolite kynurenine.

This metabolite activates AHR, which inhibits the expression of another protein called PML [promyelocytic leukemia protein, very important to the antiviral immune response] and thereby lets the virus replicate more freely in cells, Peron said.

At the University of Buenos Aires, Garcia led experiments with various cell lines including hepatocytes and neural progenitors, stem cells that have the capacity to differentiate into neuronal and glial cells.

We treated the cell lines with AHR agonist compounds [which magnify the action of the protein] and AHR antagonists [which inhibit it], Garcia toldAgncia FAPESP. In this manner we confirmed that negative modulation of this receptor inhibits replication of zika. In the same way we demonstrated that positive modulation boosts viral replication in cells.

Environmental factors

The impact of the 2015 zika epidemic was highly asymmetrical, Garcia said. In some regions and cities, the incidence of the congenital syndrome and microcephaly caused by the virus was much higher than in others. In her view this may be because of environmental factors favoring infection in the worst-hit areas or because their inhabitants were more susceptible. Both factors may also have contributed simultaneously to an intensification of zikas impact.

Coincidentally, AHR can be activated by environmental pollutants, and by certain diets or endogenous microbiota. Our next challenge is to rule out or confirm the existence of a link between AHR, polluted or socio-economically degraded environments and heightened virulence of zika, Garcia said.

The article AHR is a zika virus host factor and a candidate target for antiviral therapy can be read at:https://doi.org/10.1038/s41593-020-0664-0.

See more here:
Zika: Research team use experimental drug that reduces replication of the virus and prevents microcephaly in mice - Outbreak News Today

New Report On, Stem Cell Therapeutics Market 2020 Top Countries Industry Demand, Impressive CAGR of 13.7%, Share, Size, Future Trends Plans, Growth…

By adminJuly 21, 2020Stell Cell Research

INC. and CAPRICOR THERAPEUTICS INC.

Brief Description about Stem Cell Therapeutics market:

The Behavioral Rehabilitation Market is expected to witness a CAGR of 13.7% during the forecast period. North America dominates the global market due to the high incidence diseases such as cancer and diabetes which can now be cured by stem cell therapies.

Increased Awareness about Umbilical Stem Cells

Currently, there is an increase in the number of clinical trials for testing future treatment possibilities of cord blood. Over 200 National Institutes of Health (NIH) funded clinical trials with cord blood are currently being conducted in the United States alone. The potential implications of the results are a cause of hope among scientists and healthcare providers. In the United Kingdom, a petition has been submitted to increase the awareness of umbilical cord cells. In United States, CordBloodAwareness.org was created out of a need to increase awareness about the life-saving power of umbilical cord blood stem cells. Thus increasing awareness about umbilical stem cells. Additionally, increase in the patient population, increase in the approval for clinical trials in stem cell research, growing demand as regenerative treatment option and rising R&D initiatives to develop therapeutic options for chronic disease are also fuelling Stem Cell Therapeutics Market globally.

Ethical and Moral Framework

Stem cells are often viewed as a hope as an alternative form of therapies. However, there has been a strong debate over the use of stem cells in the development of novel therapies. It is a matter of high priority on the political and ethical agenda of many countries. As much as there is a great scope on the therapeutic front, there is an equally strong opposing force on the ethical front. For example, embryonic stem cell research is a morally complex scenario. There are different viewpoints on this issue. Embryos are considered as a Person or as a potential Person. This is one side of the moral issue which is being catered to which is restraining the growth of stem cell therapeutics market. Additionally, expensive procedures and regulatory complications are also hindering the growth of Stem Cell Therapeutics Market.

North America is dominating the market

One of the largest driving factors for the stem cell market in the US is the high purchasing power of the citizens in the country. There is an increasing incidence diseases such as cancer and diabetes which can now be cures by stem cell therapies. There is also increased awareness about the available stem cell procedures and therapies among people which in turn increases the demand for this market. Thus North America dominates Stem Cell therapeutics Market.

Request a Sample Copy of the Stem Cell Therapeutics Market Report 2020

Research objectives:

Major Countries play vital role in Stem Cell Therapeutics market:

Inquire or share your questions if any before the purchasing this report @ https://www.360researchreports.com/enquiry/pre-order-enquiry/13102459

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Detailed TOC of Global Stem Cell Therapeutics Market Segmented by Platform, Purpose, and Geography Growth, Trends

1.Introduction

1.1 Study Deliverables

1.2 General Study Assumptions

2.Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Study Phases

2.4 Econometric Modelling

3.Executive Summary

4.Market Overview and Trends

4.1 Introduction

4.2 Market Trends

4.3 Porters Five Force Framework

4.3.1 Bargaining Power of Suppliers

4.3.2 Bargaining Power of Consumers

4.3.3 Threat of New Entrants

4.3.4 Threat of Substitute Products and Services

4.3.5 Competitive Rivalry within the Industry

5.Market Dynamics

5.1 Drivers

5.2 Restraints

Continued

Purchase this report (Price 4250 USD for a single-user license) @ https://www.360researchreports.com/purchase/13102459

About 360 Research Reports:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact:

360 Research Reports

Mr. Ajay More

USA :+1 424 253 0807

UK :+44 203 239 8187

[emailprotected]

related reports:

Cooling Vests Market Research Reports 2020 | Global Top Countries Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by 360 Research Report

Ice Hockey Skate Market 2020 Global Top Countries Industry Size, Share, Business Growth, Revenue, Trends, Market Demand Penetration and Forecast to 2024

See the rest here:
New Report On, Stem Cell Therapeutics Market 2020 Top Countries Industry Demand, Impressive CAGR of 13.7%, Share, Size, Future Trends Plans, Growth...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis & Technological Innovation – Jewish Life News

By adminJuly 21, 2020Stell Cell Research

Data Bridge Market Research has recently published the Global research Report TitledAutologous Stem Cell and Non-Stem Cell Based Therapies Market. The study provides an overview of current statistics and future predictions of the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Order a Free Sample Copy of thisAutologous Stem Cell and Non-Stem Cell Based Therapies Market Report:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

List of Companies Profiled in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report are:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Major Regions as Follows:

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trendsand Forecast to 2026

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is spliton the basis of the categories of products and clientapplication segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step on the way tobe a milestone ingrowingandexpandingtheirorganizationsinside theworldwideAutologous Stem Cell and Non-Stem Cell Based Therapies market.

How Does This Market Insights Help?

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart):https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The report highlights current and future market trends and carries out an analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Autologous Stem Cell and Non-Stem Cell Based Therapies market report include market definition, market segmentation, key developments, competitive analysis and research methodology.

Why choose us:

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

To Get the Short-Term and Long-Term Impact of COVID-19 on this Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Link:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis & Technological Innovation - Jewish Life News

New Research on Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2026 Industry Size, Share, Types, Regional Analysis, Manufacturers…

By adminJuly 21, 2020Stell Cell Research

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2020 to 2026. Increasing prevalence of chronic diseases and adaptation of advanced technology are driving the market growth. However high cost of the therapy might restraint the market growth

For Sample Copy of this Report @ https://www.orianresearch.com/request-sample/1131253

What You Can Expect From Our Report:

Autologous Stem Cell and Non-Stem Cell Based Therapies Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Market Segment by Manufacturers:

Report Covers Market Segment by Types:

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report 2020 @ https://www.orianresearch.com/checkout/1131253

Report Covers Market Segment by Applications:

Key Benefits of the Report:

Target Audience:

Inquire more about Autologous Stem Cell and Non-Stem Cell Based Therapies Market report @ https://www.orianresearch.com/enquiry-before-buying/1131253

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the

Key Industry Participants (KIPs) which typically include:

Table of Content

1 Executive Summary

2 Methodology And Market Scope

3 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Outlook

4 Autologous Stem Cell and Non-Stem Cell Based Therapies Market By End User

5 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Type

6 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Mesenchymal Stem Cells Market Market Will Witness Substantial Growth in the Upcoming Years – 3rd Watch News

By adminJuly 21, 2020Stell Cell Research

CMI announced that its published an exclusive report namely Global Mesenchymal Stem Cells Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Mesenchymal Stem Cells Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.

Download PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/720

The report presents an overview of Mesenchymal Stem Cells Market consist of objectives study and definition of Mesenchymal Stem Cells. The next section focuses on market size, region-wise Mesenchymal Stem Cells growth rate estimation from 2020-2027.

This research report categorizes the global market by players/brands, regions, types, and applications. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porters Five Forces Analysis.

Key Manufacturers Analysis:Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Mesenchymal Stem Cells Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

North America (the USA, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Columbia, etc.) The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Following market aspects are enfolded in Global Mesenchymal Stem Cells Market Report:

A wide summarization of the Global Mesenchymal Stem Cells Market. The present and forecasted regional market size data based on applications, types, and regions. Market trends, drivers, and challenges for the Global Mesenchymal Stem Cells Market. Analysis of company profiles of Top major players functioning in the market.

Mesenchymal Stem Cells Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Mesenchymal Stem Cells Market players in detail. Mesenchymal Stem Cells Market report gives key bits of the Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/720

Key questions answered in Report:-

Mesenchymal Stem Cells Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027 Consumption Analysis of Mesenchymal Stem Cells, Guidelines Overview and Upcoming Trends Forecast till 2027 Mesenchymal Stem Cells Market Top Companies Sales, Price, Revenue and Market Share Outlook Mesenchymal Stem Cells Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 Analytical Overview, Growth Factors, Demand and Trends Mesenchymal Stem Cells by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027 Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast Mesenchymal Stem Cells Overview, Raw Materials Analysis, Market Drivers and Opportunities In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Email: [emailprotected] United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050-5539-1737 India: +91-848-285-0837

Stay Home. Stay Safe. Save Lives.

View post:
Mesenchymal Stem Cells Market Market Will Witness Substantial Growth in the Upcoming Years - 3rd Watch News

Global Stem Cell Therapy Market Report Examines Analysis By Size, Share, Latest Trends, Future Growth, Top Key Players And Forecast To 2027 – Jewish…

By adminJuly 21, 2020Embryonic Stem Cells

The New Report Titled as Stem Cell Therapy Market published by Global Marketers, covers the market landscape and its evolution predictions during the forecast period. The report objectives to provide an overview of global Stem Cell Therapy Market with detailed market segmentation by solution, security type, application and geography. The Stem Cell Therapy Market is anticipated to eyewitness high growth during the forecast period. The report delivers key statistics on the market status of the leading market players and deals key trends and opportunities in the market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request_sample

This research report also includes profiles of major companies operating in the global market. Some of the prominent players operating in the Global Stem Cell Therapy Market are:

Celgene Corporation Osiris Therapeutics, Inc. Pharmicell Co., Ltd MEDIPOST Co., Ltd. Promethera Biosciences Fibrocell Science, Inc. Holostem Terapie Avanzate S.r.l. Cytori Therapeutics Nuvasive, Inc. RTI Surgical, Inc. Anterogen Co., Ltd. RTI Surgical, Inc

The Stem Cell Therapy Market for the regions covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Regional breakdown has been done based on the current and forthcoming trends in the global Stem Cell Therapy Market along with the discrete application segment across all the projecting region.

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/57925

The Type Coverage in the Market are:

Adult Stem Cells Human Embryonic Induced Pluripotent Stem Cells Very Small Embryonic Like Stem Cells

Market Segment by Applications, covers:

Regenerative Medicine Drug Discovery and Development

Some Major TOC Points:

Chapter 1. Stem Cell Therapy Market Report Overview

Chapter 2. Global Stem Cell Therapy Market Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Stem Cell Therapy Market Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Stem Cell Therapy Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

Continue for TOC

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

Key questions Answered in this Stem Cell Therapy Market Report:

What will be the Stem Cell Therapy Market growth rate and value in 2020?

What are the key market predictions?

What is the major factors of driving this sector?

What are the situations to market growth?

Major factors covered in the report:

Global Stem Cell Therapy Market summary

Economic Impact on the Industry

Stem Cell Therapy Market Competition in terms of Manufacturers

Stem Cell Therapy Market Analysis by Application

Marketing Strategy comprehension, Distributors and Traders

Study on Market Research Factors

Table of Content & Report Detail @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table_of_contents

See the rest here:
Global Stem Cell Therapy Market Report Examines Analysis By Size, Share, Latest Trends, Future Growth, Top Key Players And Forecast To 2027 - Jewish...

In Remission for 10 Years: Long-term Data on CAR-T Therapy – Medscape

By adminJuly 21, 2020Stem Cell Medical Center

When a patient with cancer hears there isn't much left that doctors can do, it always stays fresh in the mind.

Doug Olson was first diagnosed with chronic lymphocytic leukemia (CLL) over 20 years ago, in 1996. For several years, his doctors used the watch-and-wait approach. But then his cancer progressed and needed treatment. By 2010, it had mutated so much that it no longer responded to standard therapy.

He was rapidly running out of options. Back then, the only treatment left was a bone marrow transplant. Without one, his doctors said, he would have 1 or 2 years left to live.

"I was really trying to avoid a bone marrow transplant. You're playing your last card if that doesn't work. It's a pretty rough procedure," Olson told Medscape Medical News.

Looking back, Olson counts himself as lucky for being in the right place, at the right time, with the right doctor. His oncologist was David Porter, MD, the principal investigator on a trial at the University of Pennsylvania that was investigating a brand new approach to treating cancer: chimeric antigen receptor (CAR) T-cell therapy.

CAR T-cell therapy uses a patient's own T cells engineered to express a receptor that targets proteins on cancer cells. CAR T cells are considered "living drugs" because they expand inside the body and stick around for years maybe for a lifetime to fight the cancer if it tries to come back.

"I was certainly intrigued by the approach. It had worked in mice, and it was the sort of thing that looked like it would work," Olson recalled.

Science is not a foreign language to Olson. He holds a PhD in medicinal chemistry, spent most of his career in the in vitro diagnostics industry, and currently acts as chief executive officer of Buhlmann Diagnostics Corp.

So he read the clinical protocol for the first in-human trial of CAR T cells and agreed to become patient number two.

Olson's T cells were harvested, engineered to attack the CD19 antigen found on malignant and normal B lymphocytes, and then were expanded into millions in the lab. After undergoing preconditioning with chemotherapy to minimize rejection and boost the CAR T cells' expansion inside the body, he received several infusions of the new therapy over the course of 3 days.

Nothing really happened for 2 weeks. Then he developed severe flu-like symptoms so bad that he was hospitalized.

Ironically, getting sick was a sign that the CAR T cells were working. Olson was experiencing one of the main short-term effects of CAR T-cell therapy: cytokine release syndrome. Symptoms include extremely high fevers and dangerous drops in blood pressure that can potentially cause end-organ damage.

In the early trials of these products, some patients experienced such a severe reaction that they needed intensive care, and some died. With increasing clinical experience, doctors have learned to control the reaction with the use of steroids and interleukein-6 inhibitors such as tocilizumab (Actemra).

Fortunately for Olson, the reaction passed, and he was eventually discharged.

Then the "aha moment" happened. Four weeks after receiving the CAR T cells, Olson found out that he was cancer free.

"It still gives me shivers," he said. "Dr Porter said, 'Your bone marrow's completely free. We just can't find a cancer cell anywhere.' "

The remission has lasted, and it is now 10 years later.

Long-term data have been accumulating for these novel therapies since Olson's treatment in 2010. This is particularly important for CAR T-cell therapy, because of its longevity. Because these are living cells and are expected to persist in the body for years, there is great interest in longer-term data, especially the risks for toxicity.

The FDA requires clinical follow-up for at least 15 years for patients treated with CAR T-cell therapy or any other genetically modified cells.

So far, most of the experience with CAR T cells comes from anti-CD19-directed therapy, which has shown "remarkable" remission rates in the 50% to 85% range, said Nirali Shah, MD, head of the hematologic malignancies section of the Pediatric Oncology Branch at the National Cancer Institute (NCI).

The most recent results presented at this year's annual meeting of the American Society of Clinical Oncology support earlier efficacy data, she noted. In the longest follow-up to date, researchers reported remissions lasting over 9 years in patients with relapsed/refractory B-cell lymphoma or CLL treated with Kite's axicaptagene cilleucel (Yescarta), one of two anti-CD19-directed CAR T-cell therapies approved by the FDA in 2017 (the other is Novartis' tisagenlecleucel [Kymriah]).

This study included 43 patients and showed an overall remission rate of 76%. Complete remission was achieved in 54% of patients, and 22% had partial remission.

The other focus is long-term safety. Although some of the long-term adverse effects are known and are manageable, others fall into the theoretical realm. In early May 2020, the NCI held a multidisciplinary virtual conference on CAR T-cell therapy "to encourage collaborative research about the subacute and potentially long-term toxicity profile of these treatments."

"We know just a little at this point about late- and long-term effects of CAR-T therapy, because we are relatively early in the era of CAR T cells," said Merav Bar, MD, from the Fred Hutchinson Cancer Research Center in Seattle, Washington.

What is known is that B-cell aplasia represents the most common long-term adverse effect of CAR T-cell therapy. B-cell aplasia results when anti-CD19 CAR-T therapy wipes out healthy B cells as well as the malignant ones responsible for leukemia/lymphoma.

As major players in the immune system, B cells are a key defense against viruses. So B-cell aplasia represents a very specific type of immunosuppression. It is generally less severe than immunosuppression that occurs after organ transplant, which hits the immune system pretty much across the board and carries a much higher risk for infection.

The main concern is what happens when someone with B-cell aplasia encounters a new pathogen, such as SARS-CoV-2.

After infection, B cells generate memory cells, which are not killed off by anti-CD19 therapy and that stick around for life. So a patient such as Olson would still make antibodies that fight infections they experienced before receiving CAR-T therapy, such as childhood chickenpox. But now they are unable to make new memory cells, so these patients receive monthly immunoglobulin infusions to protect against pathogens they have not previously encountered.

Olson takes this in stride and says he isn't overly worried about COVID-19. He follows the recommended precautions for a man his age. He wears a mask, washes his hands frequently, and tries to maintain social distancing. But he doesn't stay locked up in his New Hampshire home.

"I took the attitude when I was diagnosed with cancer that I'm going to live my life," he said. "Quality of life to me is more important than quantity."

Another problem is the possibility of neuropsychiatric toxicity. Past studies have reported a wide range of such toxicities associated with CAR T-cell therapy, including seizures and hallucinations. Most have occurred early in the course of treatment and appear to be short-lived and reversible. However, there remain questions about long-term neuropsychiatric problems.

In a long-term study of 40 patients with relapsed/refractory CLL, non-Hodgkin lymphoma, and ALL, nearly half of patients (47.5%, 19/40) self-reported at least one clinically meaningful negative neuropsychiatric outcome (anxiety, depression, or cognitive difficulty) 1 to 5 years after anti-CD19 CAR T-cell therapy. In addition, 37.5% (15/40) self-reported cognitive difficulties.

"Patients with more severe neurotoxicity showed a trend for more cognitive difficulties afterwards," said Bar, senior author of the study.

However, teasing out the role that CAR T-cell therapy plays in these problems poses a challenge. All of these patients had been heavily pretreated with previous cancer therapy, which has also been associated with neuropsychiatric problems.

"So far, we don't know what caused it," Bar said. "Nevertheless, people need to pay attention to neuropsychiatric symptoms in CAR T-cell therapy. It is important to continue to monitor these patients for these issues."

Another potential problem is graft-vs-host disease (GVHD). This is not uncommon after hematopoietic stem cell transplants. It develops when the donor T cells view antigens on healthy recipient cells as foreign and attack them.

For patients who are treated with CAR T cells, GVHD is mostly a concern among individuals who have previously had a transplant and who are already at increased risk for it.

In a study of late effects among 86 adults treated with anti-CD19 CAR T cells for relapsed/refractory non-Hodgkin lymphoma, Bar and colleagues found that GVHD occurred only among patients who had received a previous donor stem cell transplant. Of these, 20% (3/15) developed GVHD about 28 months after CAR-T therapy.

"The data for CAR T cells causing GVHD really hasn't shown that it's a huge problem, although we have seen it and are continuing to monitor for it," the NCI's Shah commented to Medscape Medical News.

A range of other long-term adverse effects have been reported with CAR-T therapy, including prolonged cytopenias (reduced mature blood cells), myelodysplasia (bone marrow failure), and second malignancies.

In the study with the longest follow-up to date, 16% (7/43) of patients developed second malignancies, which is comparable to data from Bar's study in Seattle (15%, 13/86). The researchers in this study consider this rate to be no higher than expected: these patients had already received extensive chemotherapy, which increases the risk for other cancers, they point out.

However, this brings up theoretical concerns about the long-term effects of gene modification. CAR T cells are engineered using retroviruses (mainly lentiviruses), which randomly insert the CAR genes into the host genome. Doing so may cause mutations that could promote cancer. These lentiviruses also carry the theoretical risk of becoming capable of viral replication once inside the body.

To address these concerns, viruses used to engineer CAR T cells go through comprehensive safety testing. After therapy, patients are checked every few months during the first year and annually after that.

So far, there have been no reports of cancers associated with CAR T-cell therapy.

"Any type of cancer is a very theoretical risk," Bar told Medscape Medical News. "Most likely the malignancies in our study were related to prior treatment that the patients received. None of them had any evidence of replication-competent lentivirus, or any other evidence that the malignancies were related to the CAR T cells."

Another theoretical concern is the possibility of new-onset autoimmune disease, although, once again, no cases have been reported so far.

"We think of it as a theoretic possibility. Whenever you jack up the immune system, autoimmune disease is a potential risk," said Carl June, MD, director of the Center for Cellular Immunotherapies at the University of Pennsylvania.

June was the coprincipal investigator of the trial in which Olson participated. He is also the inventor on patents for CAR T cells licensed by the University of Pennsylvania to Novartis and Tmunity and is a scientific founder with equity in Tmunity.

Still, autoimmunity could occur, and scientists are looking out for it.

"We are continuing to be vigilant in our monitoring for autoimmune disease," Shah added. "We've been doing CAR T-cell therapy since 2012, and I think we have yet to see true autoimmunity beyond GVHD."

In the 10 years since Olson received CAR T-cell therapy, an entire industry has sprung up. Over 100 companies worldwide are now developing CAR T-cell therapies targeting various antigens. These therapies are directed at about 60 different tumor types, including solid tumors. Nearly 200 clinical trials are underway, though most are still in early stages: as of September 2019, only 5% had reached phase 3.

Clinical data show promising results for CAR T-cell therapy directed against CD22 (overexpressed on ALL cells), and BCMA (found on almost all multiple myeloma cells). Yet questions remain as to whether CAR T cells will be as effective if they target antigens other than CD19 or cells other than B lymphocytes. One of the biggest research questions is whether they will be effective against solid tumors.

One research avenue being watched with great interest is the development of universal CAR T cells. So far, such products are at very early stages of development (phase 1 trials), but they are attractive because of the potential advantages they offer over bespoke CAR T cells. Automating the process holds the promise of immediate availability, standardizing production, expanding access, and lowering costs. And because the T cells for this universal product come from healthy donors, they may function better than T cells that have been battered and bruised by past cancer treatments, or even the cancer itself.

However, precisely because they are developed from healthy donor T cells, universal CAR T cells may pose increased risk for GVHD. Scientists are trying to get around this problem by engineering universal CAR T cells that lack the T-cell receptor involved in GVHD.

There are also other concerns. Nature has a penchant for mutation. Engineering CAR T cells without T-cell receptors means the body may no longer detect or reject a universal CAR T cell if it goes rogue. Also, gene insertion in universal CAR-T therapy is targeted rather than random (as in bespoke CAR T cells), which could create off-target effects. Both issues create a theoretical risk of such products inducing an untreatable CAR T-cell therapyassociated cancer.

"The theoretic risk with universal cells is that their safety profile may not be as good for long term," June commented.

From that first trial in which June and Porter used CAR T cells, two of three patients they treated are still alive 10 years later.

Olson is one of these two, and he still undergoes monitoring every 3 months to check for relapse. So far, none of his tests have shown signs of his cancer returning.

After going into remission, Doug spent the next 6 to 9 months regaining his health and strength.

"I figured if I had this amazing treatment that saved my life, I had an obligation to stay alive," he said. "I'd better not die of something like a heart attack!"

He took up long distance running and has completed six half marathons. He became involved in the Leukemia and Lymphoma Society, participating in fund-raising and helping newly diagnosed patients. Over the years, he has also given talks for researchers, people with cancer, and healthcare providers.

Doug is now 73. Today, he marvels at how rapidly the CAR-T field has progressed.

"Twenty years ago, if you had cancer, your prospects weren't nearly as good as these days. In 2010, people still didn't believe in CAR T-cell therapy," he said. "My goal always in telling my story is a message of hope."

For more from Medscape Oncology, join us on Twitter and Facebook.

More here:
In Remission for 10 Years: Long-term Data on CAR-T Therapy - Medscape